Tag: GEP-NETs
-
Dose Escalation for Somatostatin Analogs in GEP-NETs: Why Higher Doses Could Matter
Understanding the current landscape Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a range of clinical challenges, from symptom control to tumor progression. Somatostatin analogs (SSAs) such as octreotide LAR and lanreotide are first-line therapies for many patients with metastatic or unresectable GEP-NETs. They help control hormone-related symptoms and often stabilize tumor growth. As trial data accumulate, physicians…
-
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs
Understanding the Debate: Dose Escalation for Somatostatin Analogs in GEP-NETs Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a heterogeneous landscape, with treatment aims centered on controlling tumor growth, managing symptoms, and preserving quality of life. Somatostatin analogs (SSAs), such as octreotide and lanreotide, have long been foundational therapies due to their ability to curb hormonal symptoms and…
-
Dose Escalation of Somatostatin Analogs in GEP-NETs: Waiting on SORENTO results
Overview: What dose escalation could mean for GEP-NET patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a challenging therapeutic landscape, often requiring targeted strategies that control tumor growth and symptom burden. Somatostatin analogs (SSAs), such as octreotide and lanreotide, have been foundational therapies, known for stabilizing disease and reducing hormone-related symptoms. However, emerging discussions in the field…